ARVINAS



Media Fact Sheet • 1 H 2025

Arvinas' PROTAC Discovery Engine

NASDAQ LISTED ARVN

WHAT ARE PROTACS?

PROteolysis **TA**rgeting **C**himeras, pioneered by Arvinas, are a new class of orally bioavailable, small molecule investigational therapies designed to specifically eliminate overexpressed or malfunctioning proteins that drive disease.

HOW DO THEY WORK?

PROTACs are designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

ARVINAS' APPROACH

Arvinas is leveraging its PROTAC technology to build out a pipeline of therapeutic candidates addressing debilitating diseases across various therapeutic areas.

MECHANISM OF ACTION

- PROTACs consist of two independent binding components that are connected by a linker. One binding component binds to the disease-causing protein and the other binds to an E3 ligase, leading to the marking of the protein for elimination. Once marked, the disease-causing protein is directed to the proteasome, the garbage disposal of the cell.
- The degraders themselves are not broken down in this process, so each PROTAC has the potential to perform this task hundreds of times.

POTENTIAL BENEFITS OF PROTACS

- Eliminate (rather than inhibit) disease-causing proteins
- Ablity to disrupt scaffolding functions of target proteins
- Ablity to bind and degrade classically "undruggable" proteins
- Orally bioavailable and able to achieve broad tissue distribution, including across the blood-brain-barrier



THE FUTURE OF PROTAC-BASED THERAPIES

Arvinas' current deep and differentiated PROTAC pipeline aims to address new treatments for patients with significant medical needs in cancer and neuroscience including breast and prostate cancer, Parkinson's disease, progressive supranuclear palsy, and subsets of non-Hodgkin Lymphoma.

INVESTOR CONTACT: Jeff Boyle | 347-247-5089 | jeff.boyle@arvinas.com
MEDIA CONTACT: Kirsten Owens | 203-584-0307 | kirsten.owens@arvinas.com